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Abstract
Background: Precision medicine in oncology relies on rapid associations between patient-specific variations and
targeted therapeutic efficacy. Due to the advancement of genomic analysis, a vast literature characterizing cancer-
associated molecular aberrations and relative therapeutic relevance has been published. However, data are not
uniformly reported or readily available, and accessing relevant information in a clinically acceptable time-frame is a
daunting proposition, hampering connections between patients and appropriate therapeutic options. One
important therapeutic avenue for oncology patients is through clinical trials. Accordingly, a global view into the
availability of targeted clinical trials would provide insight into strengths and weaknesses and potentially enable
research focus. However, data regarding the landscape of clinical trials in oncology is not readily available, and as a
result, a comprehensive understanding of clinical trial availability is difficult.
Results: To support clinical decision-making, we have developed a data loader and mapper that connects
sequence information from oncology patients to data stored in an in-house database, the JAX Clinical
Knowledgebase (JAX-CKB), which can be queried readily to access comprehensive data for clinical reporting via
customized reporting queries. JAX-CKB functions as a repository to house expertly curated clinically relevant data
surrounding our 358-gene panel, the JAX Cancer Treatment Profile (JAX CTP), and supports annotation of functional
significance of molecular variants. Through queries of data housed in JAX-CKB, we have analyzed the landscape of
clinical trials relevant to our 358-gene targeted sequencing panel to evaluate strengths and weaknesses in current
molecular targeting in oncology. Through this analysis, we have identified patient indications, molecular aberrations,
and targeted therapy classes that have strong or weak representation in clinical trials.
Conclusions: Here, we describe the development and disseminate system methods for associating patient
genomic sequence data with clinically relevant information, facilitating interpretation and providing a mechanism
for informing therapeutic decision-making. Additionally, through customized queries, we have the capability to
rapidly analyze the landscape of targeted therapies in clinical trials, enabling a unique view into current therapeutic
availability in oncology.
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Introduction
The advent of the genomic era has provided clinicians
and researchers the ability to analyze molecular data
from patients and identify genetic variants that may have
an impact on their clinical outcome and treatment op-
tions. Cancer research has additionally identified a myriad
of genetic variations that impact protein function, the
pathology of tumor cells, and potential response to tar-
geted therapies. Connecting this information to clinical
patient data is critical for the implementation of precision
medicine. However, this information is vast and disparate,
which hampers the ability to access potentially crucial in-
formation in a clinically acceptable time frame. Access to
this data requires several key components: a structured
and well-organized database for deposition of clinically
relevant data, accurate manual curation of data with lim-
ited variability, accessibility of connections between data
elements via well-defined relationships, and a system for
routinely and automatically mapping clinical sample data
to the database. A number of publicly available databases
exist that catalog cancer-related genomic variations or that
connect variations to potentially relevant therapies, but
none complement the need for connecting patient aberra-
tions to targeted therapy—either through clinical trials or
approved drugs, while incorporating supporting efficacy
information. For instance, the COSMIC database provides
an invaluable catalog of cancer-related somatic genetic ab-
errations but does not assess relationships between those
variants and therapies [1]. The My Cancer Genome data-
base from Vanderbilt incorporates efficacy data for well-
studied molecular aberrations that could prove useful in
clinical interpretation [2]. However, the content is con-
fined to a small variant list and is not routinely updated
and as a result, the depth and breadth of the coverage of
molecular targets and targeted therapies, as well as patient
indications and clinical trials curated is limited, effectively
hindering its utility. In addition to the scarcity of databases
populated with comprehensive targeted oncology clinical
data, a system that can directly link patient sequence data
to clinical information is lacking, and thus, the speed at
which these data can be related to targetable mutations in
tumor samples is greatly reduced.
To enable this process, we have developed a clinical bio-
informatics and curation pipeline that operates within a
Clinical Laboratory Improvements Amendment (CLIA)
and College of American Pathologists (CAP)-accredited
environment, the JAX Clinical Genome Analytics (CGA)
system. This system enables systematic identification and
annotation of clinically relevant cancer variants and facili-
tates connections to therapeutic interventions. JAX-CGA
comprises several components, including an automated
data loader and mapper, which loads called variants from
clinical samples and transforms them to Human Genome
Variation Society (HGVS) nomenclature using Human
Genome Organisation (HUGO) gene symbols and subse-
quently maps the variants to the database. In addition, our
in-house curation database, the JAX Clinical Knowledge-
base (JAX-CKB) enables dynamic curation of data connect-
ing genetic variant to phenotype and protein effect, as well
as therapeutic relevance and potential treatment ap-
proaches, which can be queried readily for clinical report-
ing. To facilitate interoperability between databases,
the JAX-CKB utilizes standardized variant nomencla-
ture and incorporates specific ontologies. HUGO,
through the HUGO Gene Nomenclature Committee
(HGNC), maintains a catalog of unique approved gene
names, which we have incorporated into the JAX-CKB,
reducing ambiguity and enabling interoperability be-
tween databases [3]. Additionally, the Human Genome
Variation Society (HGVS) provides guidelines for the
standardization of variant nomenclature, which are ac-
tively maintained and updated, facilitating unambigu-
ous variant naming [4].
A fundamental challenge to precision medicine is the
ability to easily connect a patient’s genetic variants with
a therapeutic approach, which could include either
FDA-approved targeted therapies or targeted therapies
in recruiting clinical trials. Recent studies have demon-
strated that linking patients to relevant targeted therap-
ies based on genomic data has the potential to achieve
higher clinical success relative to recruitment solely on
histological subtype [5]. Leveraging the power of an inte-
grated knowledgebase, we can identify opportunities for
clinical intervention, including available clinical trials for
targeted therapies. A comprehensive database can also
provide a unique view into the landscape of molecular
targets and therapies, uncovering potential opportunities
for new research and development. In addition to sup-
porting clinical reporting, the JAX-CKB allows visibility
into deficiencies in the characterization of potentially ac-
tionable mutations and therapeutic interventions, expos-
ing opportunities for research that have the potential to
advance cancer treatment. Here, we detail and share the
processes by which we map patient data to the knowl-
edgebase and provide a detailed view of the clinical trial
landscape in solid tumors.
Results and discussion
The organization of the CGA system (Fig. 1) incorpo-
rates several components, including the bioinformatics
pipeline, the data loader and mapper, the JAX Clinical
Knowledgebase, and reporting tools. The bioinformatics
pipeline portion of the CGA system, including its valid-
ation, is discussed elsewhere [6].
The flow of data through the CGA-CKB system begins
with the transformation and automated mapping of
patient variants to JAX-CKB. Mapped variants are then
filtered for actionability, which is defined as those with a
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related FDA-approved therapy or targeted therapy in
clinical trials. Filtered actionable variants are then linked
to treatment approaches and relevant recruiting clinical
trials using unique clinical reporting tools through drug
class or therapy, as well as by molecular criteria. This
process is facilitated by the design of the JAX-CKB data-
base, which incorporates connectivity of various data-
base attributes, through the use of standard language
and ontologies. The user interface allows for annotation
of the most current data surrounding genetic variants
and targeted therapies, on top of a system that incorpo-
rates standard ontologies and controlled vocabularies.
This data is then readily accessible via reporting and
analysis queries for both patient clinical reporting appli-
cations and for comprehensive analysis of data, including
data regarding clinical trials. To enable both clinical
reporting and analysis of clinically relevant data surround-
ing the JAX-CTP-targeted gene panel, we have imple-
mented a unique framework for managing and connecting
patient molecular data to efficacy information and rele-
vant treatment approaches in real-time.
Data loader and mapper
The data loader and mapper play a critical role in rou-
tine processing of large scale variation results from the
CGA pipeline. The roles of the data loader and mapper
are to upload genomic sequence data and integrate that
sequence data with sample meta-data and to automatic-
ally map patient variants to JAX-CKB, enabling further
queries for clinical interpretation.
The CGA loader (Fig. 2) runs as a daemon program,
which intermittently scans the file system in a cluster
server searching for new runs from the clinical analytics
(CGA) pipeline. New runs consist of either analysis results
of a new sample or repeat analysis results from a previ-
ously mapped sample. The CGA loader program addition-
ally extracts sample meta-data, such as patient diagnosis,
from our Laboratory Information Management System
(LIMS) and submits these data along with the variant call
format (VCF) files to a Restful web service.
The web service, running in a Tomcat application ser-
ver, saves all data files in the database with an initial
“pending” file status and manages the workflow of all
computational jobs in a queue. The format of each data
file is defined as a template in the database allowing an
integrated Java program, using Reflection, to dynamically
parse, transform, and map file columns to database ta-
bles and columns. During this workflow, additional fil-
tering or validation steps can be integrated for quality or
biological reasons. If an error occurs in the loading
process, the file status will be updated as “error” and a
tracking message will be logged. Following successful
completion of a job, the file status will be updated as
“loaded.”
The Mapper (Fig. 3) is the nickname of the web service
that manages the automated data loading and mapping
jobs. During the data loading workflow, sequence variants,
which include point mutations or small insertions or dele-
tions (InDels), are transformed to standard Human
Genome Variation Society (HGVS) nomenclature [4],
which is consistent with the regular expression (regex) vo-
cabulary of variants in the JAX-CKB. For example, the
SnpEff and SnpSift programs annotate an amino acid from
nucleotide sequence information using a three-letter amino
acid code (e.g., “Gly” for Glycine). This three-letter code is
then transformed to the single letter code for that amino
Fig. 1 Flow of data through the clinical pipeline. Patient sample sequence data from the clinical genome analytics (CGA) pipeline is integrated with
sample meta-data from the Laboratory Information Management System (LIMS), and called variants are mapped to the JAX-Clinical Knowledgebase
(JAX-CKB) database. The JAX-CKB incorporates information populated from various incorporated ontologies and databases, and via the curation User
Interface (UI), and is maintained using the CKB-Utilities tools. Using information from the JAX-CGA/CKB and the CKB reports, tools are used to generate
datasets to enable clinical report generation
Patterson et al. Human Genomics  (2016) 10:4 Page 3 of 13
acid, using the appropriate syntax (e.g., “G” for “Gly”). For
example, p.Gly749Glu/c.2246G >A will be transformed to
“G749E,” and the frameshift Arg34_Val35fs/c.102_103insG
will be transformed to “R34fs.” Subsequent to transform-
ation, several filtering steps have been implemented to en-
sure the use of only high-quality somatic variations and
reduce false-positives. Filters include removal of variants
with low coverage, variants with allele frequencies that do
not meet minimum requirements for sensitivity, low impact
variants including silent mutations, variants that are likely
germline, and those that are likely false-positive or outside
of coding regions. Simultaneously, Copy Number Variation
Fig. 3 Automated variant mapping process. The genomic datasets are transformed to standard Human Genome Variation Society (HGVS)
nomenclature, using a standardized Regular Expressions (regex) vocabulary incorporated into the JAX-CKB. This enables mapping and identification of
clinically meaningful variants in a scalable and reproducible manner. The variant mapping program also includes several filtering steps, including removal
of low-impact variants, those that did not pass metrics, and those that are likely germline or false-positive, to ensure reporting of only high-quality
somatic variations
Fig. 2 Automated data loading process. The data loader scans the file system hourly to find any new runs from the clinical pipeline and submits
the variant call files (VCF) along with their sample meta-data to a web service. The web service manages the data loading jobs in a queue, to
transform, filter, and upload the datasets to our CGA database and map the variants to the JAX-CKB
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(CNV) files are filtered to remove genes with fewer than six
copies, based on the analytical validation of the assay [6].
Following filtering, CNV files are merged with the filtered
VCFs. The analytics program will then automatically
recognize and map the variants in the JAX-CKB, enabled
by the transformation to the HGVS syntax used by JAX-
CKB.
This process allows for direct connectivity between
clinically actionable somatic variants present in patient
tumor samples with applicable clinical data.
Database queries and clinical reporting tools
While compiling and organizing clinically relevant data
has utility, the power to utilize these data lies in the abil-
ity to easily access and leverage complex data to inform
clinical decision-making. To that end, we have designed
and implemented several database queries, which both
facilitate reporting and enable unique views into the data
for analysis and quality assurance.
Following the mapping of samples to the JAX-CKB,
mapped variants are filtered and displayed in a JAX-CKB
reporting application. From the sample landing page, a
user can select the relevant sample and launch queries
directly from the sample results, allowing the user to
tailor the queries to sample-specific molecular aberra-
tions while providing traceability. Several queries have
been built to generate result sets that support clinical
reporting. The queries are designed to run based on all
clinically relevant variants in a single sample simultan-
eously; however, the search page for each query incorpo-
rates a selection tool from which a user can deselect any
variant in the sample to exclude as search parameters.
This enables the user to run the queries on only variants
that have clinical relevance, as well as limiting query re-
sults from samples with many actionable variants to pro-
duce multiple, more manageable, datasets. To retrieve
the list of targeted therapies associated with sample-
specific variants, we have designed a query that utilizes
the associated drug class or individual therapy treatment
approaches specific to variants to retrieve all drugs
assigned to those treatment approaches. For example,
the variant KIT D816V has the associated treatment ap-
proach “KIT Inhibitors.” There are currently 31 drugs
curated into JAX-CKB that have been assigned the drug
class “KIT Inhibitors.” If present in a mapped sample in
CKB, launching the drug query retrieves the drug class
treatment approach for KIT D816V and from this re-
trieves the list of drugs associated with this drug class.
In addition, there are three separate queries that leverage
different aspects of curated efficacy evidence. The ap-
proval status query retrieves data from the “approval sta-
tus” attribute of curated efficacy evidence for all drugs
related to treatment approaches for given variants. This
enables identification of targeted therapies that are FDA-
approved versus investigational therapies, related to a
treatment approach for the patient variant(s). The drug
resistance query retrieves efficacy evidence entries for
all molecular profile responses with response type of
“resistant” that contains the same parent gene of
sample-specific variants. For example, for a sample con-
taining a KRAS G12C variant, the resistance query would
retrieve all resistance efficacy evidence associated with any
molecular profile response containing a variant in KRAS.
This would include the efficacy evidence related to KRAS
G12C, as well as category variants “KRAS G12X” and
closely related variants KRAS G12D and KRAS G13C. Re-
lating to parent gene, rather than specific variant, enables
visibility into all potential resistance mechanisms without
requiring duplication of data in CKB. A third query pulls
all evidence with sensitive response type related to the
treatment approach for patient variants, to support ration-
ale for therapies included on patient reports.
Clinical trial query
Clinical trials function as an avenue toward clinical
intervention and constitute an important component
of the therapeutic landscape for oncology patients.
Thus, we have incorporated the identification of
clinical trials relevant to patient variants into clinical
reporting to provide multiple potential options for
clinicians to direct patient treatment. Clinical trials
can be relevant to patient variants via inclusion of
drugs contained in variant treatment approaches, or
through molecular inclusion criteria. To retrieve a list
of open clinical trials related to sample variants, we
have implemented a complex query that retrieves
clinical trials both for drugs in treatment approaches
and those that contain molecular criteria for the parent
gene associated with sample variants, irrespective of
therapy. Clinical trials are queried first by drugs con-
tained in variant treatment approaches, and for result-
ing trials containing those drugs, data is retrieved and
displayed including NCTID, sponsor, title, and therapy,
as well as a column including the variant for which the
trial was pulled. Clinical trials are also queried on par-
ent gene, excluding all trials with a requirement for
wild-type. Clinical trials can be further restricted
through the selection of Disease Ontology terms, re-
lated to patient indication. The Disease Ontology (DO)
is a robust, regularly maintained, ontology of standard-
ized disease terms, each backed by individual unique
identifiers (DOIDs), which facilitates precise mapping
to patient diagnosis [7]. When selected, returned trials
will include only those that are related to the selected
DOID and all child terms. This process is enabled by
the integration of the DO tree in clinical trial curation,
which can be employed for retrieval of only those trials
relevant to the patient’s indication.
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Clinical trial landscape
Outside of CKB, there are currently no publicly available
comprehensive databases that curate information on
molecular eligibility for clinical trials. Access of clinical
trials recruiting on molecular criteria is not readily ac-
cessible through clinical trial registries, such as clinical-
trials.gov, which is primarily the result of a lack of
standardization of nomenclature and syntax for molecu-
lar eligibility criteria in clinical trial registries [8]. One
significant potential outcome of this is an inadequate
representation of potentially relevant clinical trials for
clinicians performing a cursory keyword search. In
addition, the lack of molecular criteria accessibility likely
increases the time necessary for identifying potentially
relevant trials, as a clinician must sort through the trial
record to identify molecular inclusion criteria. To exped-
ite retrieval of relevant clinical trials and streamline the
path toward clinical intervention based on molecular
variant, we have incorporated manual curation of mo-
lecular eligibility into the JAX-CKB database to easily
connect patients with trials that are relevant to findings
from next-generation sequencing.
In addition to providing a path to intervention in clin-
ical reporting, the organization and design of the JAX-
CKB (discussed below) allows us to readily analyze the
current landscape of clinical trials. This analysis of the
relative number of clinical trials for drug class or mo-
lecular criteria enables a view into the strengths and
weaknesses in targeting actionable variants in clinical tri-
als. Previous analysis of the landscape of cancer clinical
trials in the USA, in the absence of a structured curated
database, has required significant effort using data ex-
tracted manually via keyword search of clinicaltrials.gov
[9]. The organization of data elements curated into the
JAX-CKB database facilitates rapid analysis of data from
clinical trials through customized queries of the database.
Using these queries, we have analyzed the landscape of tri-
als restricted to those currently open (defined as those
with the recruitment status of “not yet recruiting,”
“recruiting,” or “available”) related to our 358-gene
targeted panel.
When broken down by patient indication (Fig. 4),
19.1 % of open trials curated into the JAX-CKB are
recruiting patients with advanced solid tumors with
Fig. 4 Analysis of JAX-CKB curated clinical trials by solid tumor indication. Disease Ontology terms selected as patient indication for greater than
20 clinical trials plotted relative to the number of open clinical trials recruiting on each indication
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unspecified histology (398/2058; Fig. 4). This comprises
the largest proportion of curated clinical trials and likely
represents early stage trials for therapeutics that have
not demonstrated clinical utility in specific tumor types.
Other well-studied indications are highly represented in
clinical trials (Fig. 4), particularly those for which a re-
curring molecular target has been identified. These in-
clude non-small cell lung cancer (13.23 %; 274/2058),
melanoma (8.0 %; 167/2058), ERBB2 (Her2)-receptor
negative breast cancer (4.8 %; 100/2058), prostate adeno-
carcinoma (4.7 %; 96/2058), glioblastoma multiforme
(4.3 %; 89/2058), and head and neck squamous cell car-
cinoma (4.0 %; 83/2058) (Fig. 4). There are 96 indications
present as inclusion criteria in only a single open clinical
trial for a targeted therapy, representing an unmet need
for these patients. These indications include rare cancers,
such as chordoma (NCT01407198) and hemangiopericy-
toma (NCT01396408), which have very little data sur-
rounding targeted therapeutic efficacy, and accordingly
very few promising treatment options [10, 11].
Independent of histology, patients may enter clinical
trials based on molecular eligibility, either through a mo-
lecular aberration that is targeted by an agent in the
trial, or a trial that is directly recruiting on the presence
of a specific molecular criterion, irrespective if the
investigated therapy has demonstrated a connection to
the molecular target. Drug classes are a proxy for treat-
ment approach, and identifying the number of clinical
trials investigating drugs within specific drug classes
provides insight into the availability of targeted therapies
for molecular aberrations. In an analysis of the most fre-
quent drug classes containing drugs currently under in-
vestigation in open clinical trials, we have determined
that Pan-VEGFR Inhibitors (378/2168; 17.4 %), KIT In-
hibitors (312/2168; 14.4 %), Pan-PDGFR Inhibitors (208/
2168; 9.6 %), and RET Inhibitors (205/2168; 9.5 %) are
most highly represented (Fig. 5). This suggests that pa-
tients with activating mutations in KDR (VEGFR2), KIT,
PDGFR, and RET, depending on indication, may have
several options for potential therapeutic intervention
through recruiting clinical trials. In contrast, the drug
classes DNMT1 inhibitors, EZH2 inhibitors, and FGFR3
antibody are among those represented in a single open
clinical trial, which suggests that patients harboring gen-
etic aberrations targeted by these drug classes may have
fewer options.
Clinical trials may also recruit patients based directly
on molecular eligibility, which may be restricted to spe-
cific molecular aberrations, or a wider category of mo-
lecular aberrations. For instance, a patient with an exon
Fig. 5 Analysis of open clinical trials related to drug class. Chart displays the number of clinical trials investigating targeted drugs within specified
drug classes, for all drug classes represented in greater than 50 open clinical trials
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19 deletion in EGFR could potentially enroll in clinical
trials recruiting patients with “EGFR mutations,” “EGFR
activating mutations,” “EGFR exon 19 deletions,” or the
specific deletion harbored by this patient. Currently, the
top 5 molecular criteria in open clinical trials are related
to the expression of various hormone and growth factor
receptors including ERBB2, PGR, and ESR1 (Fig. 6),
which is likely related to their long-standing clinical as-
sociation with breast cancer subtyping and therapeutic
relevance [12]. Mutations in BRAF V600 have demon-
strated clinical utility as targetable aberrations [13] and
are highly represented as molecular eligibility criteria
in clinical trials, with 36 open trials recruiting on
BRAF V600 mutations at the time of this manuscript
(Fig. 6b). BRCA1 and BRCA2 mutations are also fre-
quently included as molecular eligibility criteria, with
35 and 33 open trials recruiting on these variants, re-
spectively (Fig. 6b).
EGFR aberrations are a highly represented target for
investigational therapies in clinical trials. EGFR is the
fifth most common gene associated with molecular in-
clusion criteria for open clinical trials curated into CKB,
with 86 clinical trials including EGFR-related molecular
inclusion criteria (Fig. 6a). Most of these trials are re-
lated to the well-characterized EGFR L858R and exon 19
deletion mutations (Fig. 6c), which have demonstrated
sensitivity to EGFR tyrosine kinase inhibitors (TKIs)
[14]. In contrast, EGFR exon 20 insertion mutations
demonstrate de novo resistance to EGFR TKIs and have
few options for clinical intervention [15, 16]. At the time
of this manuscript, EGFR exon 20 insertions are in-
cluded as eligibility criteria for two open clinical trials.
a
b c
Fig. 6 Analysis of number of open clinical trials relative to gene and gene variant as molecular criteria. a Combined total of clinical trials with
eligibility criteria related to individual genes. Graph displays genes that are represented by molecular eligibility criteria in two or greater clinical
trials. b Number of clinical trials for the top specific or category molecular criteria represented in clinical trials, limited to those in 10 or more
clinical trials. c Number of clinical trials for each type of EGFR molecular criteria present in open clinical trials
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Both of these trials are investigating the HSP90 inhibitor
AUY922 and are recruiting either specifically on exon 20
insertions or for EGFR mutations, including exon 20 in-
sertions. HSP90 inhibitors have not demonstrated full
clinical utility in the context of EGFR mutations but
have preclinical support [17]. In this context, HSP90 in-
hibitors do not meet the stringency for a JAX-CKB treat-
ment approach, and thus would not be an entry point
for clinical trial association for patients with EGFR exon
20 insertion mutations. Therefore, the inclusion of mo-
lecular criteria in this instance represents a mechanism
for therapeutic intervention that would not otherwise be
available.
The JAX clinical knowledgebase and curation user
interface
A critical component to accessing data for reporting or
analysis is a comprehensive structured database. Thus, we
have designed and implemented an in-house database to
support clinical reporting and analysis of clinically rele-
vant data. The JAX-CKB serves as a repository for data re-
garding oncology-relevant genetic variants and therapies
and incorporates interconnectivity between protein effect,
therapeutic efficacy, treatment approaches, and recruiting
clinical trials. CKB features a structured database frame-
work for managing clinical and biological data, into which
clinical data content is entered through a curation user
interface (Fig. 7). Data is dynamically curated by experts
to populate comprehensive content related to oncology, to
support clinical reporting, and to maintain the most up-
to-date information on therapies, response, and relevant
clinical trials. While JAX-CKB content is currently tailored
toward solid tumor clinical reporting, the framework of
the JAX-CKB is versatile and can support additional appli-
cations. The organization of the JAX-CKB is essential to
its utility in supporting clinical reporting and includes sev-
eral key elements (Fig. 3), which are outlined below.
Data elements
The JAX-CKB database incorporates several data ele-
ments, which are connected in various ways in curation
of cancer-related data.
Genes and gene variants
To support standardization and mapping of genetic vari-
ants to JAX-CKB and facilitate interoperability with
other databases, we have incorporated HUGO Gene No-
menclature Committee (HGNC) nomenclature through
the integration of approved symbols and gene names
from the NCBI Gene database into the JAX-CKB [3, 18].
By incorporating gene names from the Gene database,
genes are assigned approved symbols, removing variabil-
ity, and are additionally backed by unique numerical
gene identifiers (NCBI GeneID). Although our current
JAX Cancer Treatment Panel (JAX CTP) is limited to 358
cancer-related genes, the JAX-CKB incorporates all
known annotated human genes. This supports the rapid
pace of advancement in cancer research, as well as allow-
ing for the flexibility to support additional assays, which
would include sequencing assays for other disease types.
Naming of genetic variants in the JAX-CKB utilizes a
Regular Expression (regex) system that conforms to
Human Genome Variation Society (HGVS) nomenclature
guidelines, restricting the entry of genetic variants to a
predefined syntax and enabling mapping of variants to
JAX-CKB. HGVS maintains standards for variant naming,
which serves to eliminate ambiguity and ensure precision
when reporting data related to genetic variants [4]. Con-
forming to these standards additionally provides a mech-
anism to promote interoperability between databases.
Fig. 7 Connections between various data elements in the JAX Clinical Knowledgebase (JAX-CKB). Molecular profiles consist of one of more
molecular entities, linked to gene variants and parent genes. Molecular profiles are assigned relevant treatment approaches based on available
data from the literature on efficacy, as a therapeutic response. The therapeutic response additionally takes into account patient indication, which
is represented by an integrated disease ontology. Treatment approaches contain therapies, which consist of a single drug or combination of
drugs. These drugs can be either FDA-approved, or under investigation in clinical trials, which are additionally curated into the JAX-CKB
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Each variant type is assigned a specified syntax. For ex-
ample, a mutation resulting in a single amino acid change,
such as the gene variant KRAS G12C, would follow the
syntax [ACDEFGHIKLMNPQRSTVWY][0-9] + [ACDEF-
GHIKLMNPQRSTVWY]. The regex syntax is periodically
updated to maintain compliance with HGVS guidelines.
The JAX-CKB additionally incorporates controlled vo-
cabularies regarding protein effect, to annotate functional
relevance of specific variants. This aids in the interpret-
ation of actionability and provides a further mechanism
for filtering gene variants. Gene variants are linked to a
parent gene and can include any alteration to the gene,
supporting multi-omic data curation. Examples of variants
include mutations, changes to gene copy number, and ex-
pression changes. In addition, JAX-CKB supports annota-
tion of category variants (e.g., activating mutation,
inactivating mutation), which allows molecular profile re-
sponses and clinical trials to be curated to conditions
where they are applicable to multiple or unknown/un-
specified aberrations. For example, the category variant
“EGFR activating mutation” represents any activating mu-
tation in EGFR. There are also less broad category vari-
ants, such as “EGFR del exon 19,” which represents a
non-specified deletion within exon 19 of the EGFR gene.
These variants are also subject to regex syntax and must
meet predefined specifications. The inclusion of category
variants enables capture of information that is relevant to
bins of variants, rather than individual variants, or in con-
ditions where the applicable variants are not specified.
Within the Gene Variant Curation User Interface (UI),
there are multiple fields for data capture, each utilizing
their own specific controlled vocabularies to minimize
variability and allow for efficient analysis of curated in-
formation. The curation user interface allows users to
capture information around genetic variants related to
amino acid change, mutational impact to the protein
(e.g., missense, deletion, and frameshift), and functional
effect on the protein (e.g., gain-of function, and loss-of-
function). In addition, gene variants can be linked to
their impact on biological pathways, through the integra-
tion of a human pathway ontology from the Rat Genome
Database [19]. The gene variant UI also incorporates a
free-text annotation field for capture of specific informa-
tion on the relationship of the variant to oncogenic
transformation and protein function, which is supported
by curated references from primary literature.
Molecular profiles
A molecular profile in the JAX-CKB contains one or
more genetic aberrations, which can include mutations,
such as single nucleotide polymorphisms (SNPs), frame-
shifts, insertions, and deletions, as well as gene fusions,
copy number variations and/or changes in expression
levels. The flexibility of the molecular profile and the
ability to build complex molecular profiles allow for the
curation of therapeutic efficacy to multiple aberrations
simultaneously, rather than each variant in isolation. For
example, a molecular profile may contain a mutation,
such as the EGFR activating mutation EGFR L858R, as
well as a copy number variation, such as amplification of
the MET gene. MET amplification is a recognized mech-
anism for resistance to EGFR tyrosine kinase inhibitor
therapy [20–22], and the ability to create a complex
profile enables the curation of resistance data to the ap-
propriate complex molecular conditions.
Current research supports the idea that targeted treat-
ment of tumor driver mutations alone often leads to the
upregulation of compensatory mechanisms and/or ac-
quisition of secondary resistance mutations and that util-
izing a multi-target approach may be beneficial in
reducing the potential for resistance [23]. For example,
the ability to assign treatment approaches and curate ef-
ficacy evidence to multiple aberrations simultaneously
enables JAX-CKB and downstream clinical reporting to
stay on-pace with clinical progress in the use of combin-
ation therapies in complex multi-omic conditions.
Drugs and therapies
A key component to capture response data related to
molecular targets is a comprehensive database of rele-
vant drugs, which are incorporated as data elements into
JAX-CKB. Attributes associated with drugs include drug
name, trade name, and synonyms, in which each are re-
quired to be unique terms within a drug record, and
among other records, to effectively eliminate redun-
dancy. CKB currently contains 1108 unique targeted
therapies relevant to treatment approaches or clinical
trials for variants related to our 358-gene panel. When
appropriate, drugs are assigned a “Drug Class,” as a se-
lectable field within the Therapy UI using an in-house
controlled vocabulary. Drug class represents a rational
group of drugs with a unified target, such as “PIK3CA
Inhibitor” for drugs that target PIK3CA. These drug
classes are then utilized as “Treatment Approaches” for
a molecular profile, which provides a link between mo-
lecular aberrations and relevant targeted therapies.
Therapies, similar to molecular profiles, are comprised of
one or more drugs. The ability to build complex therapies
supports the therapeutic trend toward using targeted
therapies in combination with other targeted therapies or
chemotherapies and enables precision and accuracy in effi-
cacy curation.
Treatment approaches
The current utility of CKB is to support clinical report-
ing for our JAX CTP panel. To this end, we have incor-
porated the selection of potential treatment approaches
for molecular profiles, which designates a relationship
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between a selected molecular profile and either a drug
class or individual therapy. Treatment approaches are
selected following extensive review of the literature sup-
porting preclinical and/or clinical efficacy, which is add-
itionally curated via molecular profile response. For
example, the gene variant PIK3CA H1047R is a gain-of-
function variant in PIK3CA [24]. Due to several lines of
evidence, PIK3CA H1047R has been assigned the drug
class treatment approaches “mTOR inhibitors,” “PI3K
inhibitors,” and “AKT inhibitors.” Each of these drug
classes is linked to a milieu of drugs with the target
mTOR, PI3K, and/or AKT, respectively. These treatment
approaches are used in the reporting queries to identify
relevant therapies and clinical trials.
Molecular profile response and efficacy evidence
An essential component of a clinical knowledgebase is
the inclusion of evidence from primary literature sources
supporting therapeutic efficacy in the context of specific
molecular variants. The “Molecular Profile Response”
element of the JAX-CKB represents the relationship be-
tween a molecular profile and indication, therapy, and
related response type. The patient indication attribute
integrates the cancer terms from the Disease Ontology
[7], which are backed by unique identifiers (DOID) and
represented in a navigable tree.
Associated with the molecular profile response is effi-
cacy evidence, which is the point of entry for literature-
based data supporting the molecular profile response. A
molecular profile response can be associated with one or
more lines of efficacy evidence. Efficacy evidence addition-
ally includes information regarding the approval status of
the associated therapy in relation to the curated evidence,
using a controlled vocabulary to designate whether the
study was preclinical, phase I, phase Ib/II, phase III, or
FDA-approved, or if the therapy-molecular profile associ-
ation is in National Comprehensive Cancer Network
(NCCN), FDA, or European Society for Medical Oncology
(ESMO) Guidelines. Curation of FDA-approval studies
links tumor type to approval status, allowing for simultan-
eous identification of targeted therapies that have achieved
FDA-approval in a patient indication. Efficacy evidence
can be categorized, using controlled vocabulary, as action-
able, which is characterized as data relating the efficacy of
the selected therapy in the context of the selected profile
response and is prioritized based on an in-house 25-tier
ranking system. Additionally, the JAX-CKB supports the
entry of prognostic and diagnostic evidence as well as
emerging evidence, which supports potential emerging
therapeutic targets.
Clinical trials
To facilitate the inclusion of relevant clinical trials in
patient reporting to provide an additional potential
avenue for therapeutic intervention, we have incorpo-
rated clinical trial content into the JAX-CKB. This add-
itionally provides a unique mechanism for the analysis
of clinical trial data, which is cumbersome through dir-
ect extraction from clinical trial databases. For the im-
port of clinical trials into CKB, we have built a utility that
searches clinical trials from clinicaltrials.gov using a pre-
defined list of targeted therapies, restricted to trials in the
USA or Canada in “cancer” that are “open,” which are de-
fined as those trials that have a recruitment status of
“recruiting,” “not yet recruiting,” or “available.” Returned
trials are matched against those in the JAX-CKB to pro-
duce a unique list of new clinical trials. Information in-
cluding NCTID, title, and recruitment status is imported,
and remaining information from the trial record that can-
not be automatically retrieved from clinicaltrials.gov is
manually curated. The NCTID serves as a unique identi-
fier for each clinical trial. The elements in the clinical trial
user interface enable connectivity to molecular aberrations
in two ways. First, an intervention attribute enables cur-
ation of therapies being tested in the clinical trial. These
therapies are selected from a drop-down list of therapies
that is populated from the therapy table. The drugs con-
tained in those therapies can then be linked to a treatment
approach via a drug class or individual therapy. Addition-
ally, clinical trial curation integrates molecular eligibility
criteria, so trials recruiting based on the presence or ab-
sence of specific molecular criteria can be easily identified.
Therefore, a patient sample with an EGFR mutation
would be linked to a trial testing erlotinib that is recruiting
on EGFR activating mutations both by the targeted
therapy and the required molecular criteria.
To ensure that we have the most up-to-date information
in the JAX-CKB regarding clinical trial status, we have
built a cron job that performs a nightly search of clinical-
trials.gov for any change to recruitment status for trials in
the JAX-CKB and automatically updates any changes to
the database. Thus, only clinical trials that have open
recruitment statuses are included on clinical reports.
The connectivity of data in JAX-CKB and the associ-
ated reporting tools enables a direct connection between
molecular aberration and targeted therapy and connects
patients to trials investigating a relevant targeted ther-
apy, but which may not be specifically recruiting on a
molecular aberration. This may have the unintentional,
beneficial consequence of increasing success and devel-
opment of targeted agents by prescreening patients out-
side of the clinical trial protocol for the presence of
relevant genomic targets.
Conclusions
Progress in patient treatment in oncology is dependent on
both a comprehensive understanding of the relationships
between molecular variants in tumors and efficacy, and
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the power to access clinically relevant information in a
timely manner. Here, we share methods and demonstrate
the implementation of a data mapper and loader and
queries for rapid retrieval of data related to clinical efficacy
to inform clinical interpretation of molecular aberrations,
supported by the structured and organized design of the
JAX Clinical Knowledgebase. In addition, global analysis
of the clinical trial landscape provides insight into the
types of targeted agents and molecular targets that are
focal points, as well as those that could be served by add-
itional investigation.
Methods
JAX-CKB mapper and JAX-CKB schema
The following versions of the JAX-CKB mapper and
database were used in analysis:
JAX-CKB mapper: Version 1.05.
JAX-CKB Schema: Version 1.4. JAX-CKB; 81 Tables.
Data analysis
For data analysis, data was retrieved from the stage ver-
sion of the JAX-CKB database using SQL queries. Due
to the dynamic nature of the data in the production
database due to continual curation, the stage database,
which is not subject to continual update, was used to
eliminate variability in the data. The stage database was
last updated on September 18, 2015, from a snapshot of
the production version of the JAX-CKB database.
Clinical trial recruitment status updating
A nightly cron job is implemented to query https://
clinicaltrials.gov/ct2/results. It parses the HTML con-
tents to obtain the trials that match the search criteria [can-
cer-related clinical trials in the United States and Canada]
and check the recruitment status of all existing trials in the
JAX-CKB database. Following comparison with the recruit-
ment status of clinical trials in the JAX-CKB database, it
updates the database and sends an email notification to
data curators if any recruitment status is changed.
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